Pfizer Inc. (PFE) on Thursday said it received marketing authorization in U.K. for its atopic dermatitis drug, Cibinqo.
Cibinqo (abrocitinib), a Janus kinase 1 (JAK1) inhibitor, has been authorized by UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and over, who are candidates for systemic therapy.
Atopic dermatitis is a chronic skin condition characterized by dry, itchy skin.
Regulatory applications for abrocitinib have been submitted to countries around the world for review, including the United States, Australia, Japan, and the European Union, Pfizer said.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.